2017 Oncology Nursing Drug Handbook

Price: $99.95
Catalog No.: Q20013
Publisher/Vendor: Jones & Bartlett Learning
Author: Gail M Wilkes, MS, APRN-BC, AOCN and Margaret Barton-Burke, PhD, RN, FAAN
Pages: 1,636
Size: 5.6 x 2.5 x 8.5 inches
Format: Softcover Book
 
2017 Oncology Nursing Drug Handbook (Q20013)

Written especially for nurses caring for patients with cancer, the 2017 Oncology Nursing Drug Handbook expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this reference provides information on effective symptom management, patient education, and chemotherapy administration.

Completely revised and updated, the 2017 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs.

New drugs include: alectinib (Alecensa), atezolizumab (Tecentriq), cabozantinib tablets (Cabometyx), cabozantinib capsules (Cometriq), cobimetinib tablets (Cotellic), colistin/polymixin B, clotrimazole, daratumumab (Darzalex), elotuzumab (Empliciti), irinotecan liposome injection (Onivyde), ixazomib (Ninlaro), melphalan for injection (Evoela), necitumumab (Portrazza), osimertinib (Targrisso), pentamidine, posaconazole, peramivir, rolapitant (Varubi) , talimogene laherparepvec (Imlygic), Tamiflu, trabectedin (Yondelis), uridine triacetate (Vistogard granules), venetoclax (Venclexta), vincristine liposome injection (Marqibo), and zanamivir.

Table of Contents

  • Cancer Treatment
    • Introduction to Chemotherapy Drugs
    • Biologic Response Modifier Therapy
    • Cytoprotective Agents
    • Molecularly Targeted Therapies
    • Chemobiotherapy for Noncancer Diseases
  • Symptom Management
    • Pain
    • Nausea and Vomiting
    • Anorexia and Cachexia
    • Anxiety and Depression
  • Complications
    • Managing Tumor-Related Skeletal Events and Hypercalcemia
    • Infection
  • Constipation
  • Diarrhea Occupational Exposure to Hazardous Drugs Common Terminology Criteria for Adverse